The effect of bradykinin on central dopamine receptors.
Bradykinin (BK) injected intraventricularly (ivc) at doses of 0.25-0.5 mug per rat potentiated the depth of fluphenazine catalepsy and depressed or abolished the symptoms of sterotypy produced by amphetamine or apomorphine. BK did not affect the level of dopamine (DA), but elevated the level of homovanillic acid in the brain, and accelerated DA turnover as measured by the rate of dopamine disappearance following treatment with alpha-methyltyrosine. The results suggest that BK inhibits the central dopamine structures by blocking the DA receptors.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D005476:Fluphenazine / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D011954:Receptors, Dopamine; D001058:Apomorphine; D005476:Fluphenazine; D001920:Bradykinin; D003913:Dextroamphetamine; D004298:Dopamine; D006719:Homovanillic Acid